.After antibody-drug conjugate (ADC) expert Seagen was sold to Pfizer in 2014 for a tremendous $43 b...
.On the heels of a stage 3 win that fell short to wow entrepreneurs, Ironwood Pharmaceuticals is bac...
.Don't cease Monte Rosa Therapeutics now. The Boston-based biotech is having a ball after authorizin...
.Welcome to this week's Chutes & Ladders, our roundup of considerable management hirings, shootin...
.Commemorating his provider's upsized going public (IPO), Septerna chief executive officer Jeffrey F...
.AbbVie has actually come back to the resource of its antipsychotic powerhouse Vraylar trying to fin...
.GenSight Biologics is weeks off of running out of loan. Once again. The biotech simply has sufficie...
.Monopar Therapeutics is bouncing back a medication from the scrap heap of AstraZeneca's unusual dis...
.With new records out on Arcus Biosciences' experimental HIF-2a inhibitor, one team of analysts esti...
.After forming a genetics treatment alliance with Dyno Rehabs in 2020, Roche is back for even more.I...
.Lundbeck is actually slashing guide worth of its $250 million Abide Therapeutics acquistion in feed...
.The integration of real-world records (RWD) right into protocol usefulness and also internet site a...
.At this year's Intense Biotech Top in Boston, our company overtook innovators in the biotech sector...
.Merck & Co. is setting down $30 thousand beforehand to buy Yale spinout Modifi Biosciences, a ba...
.Alpha-9 Oncology has raised a $175 thousand series C round to stake its own clinical-stage radiopha...
.Eye drug creator Ocuphire Pharma is actually acquiring genetics therapy programmer Opus Genes in an...
.Roche's chronic cough plan has faltered to a standstill. The drugmaker, which axed the plan after t...
.Gilead Sciences and also Merck & Co. have assisted their once-weekly HIV blend treatment past an...
.Lykos Rehabs might have shed three-quarters of its team following the FDA's rejection of its own MD...
.Septerna might be yet to disclose "any sort of meaningful professional records," yet the biotech pl...